Graticule Appoints Patrick Wulf Hanson as Chief Alliance Officer for EU Operations
5.9.2023 17:00:00 EEST | Business Wire | Press release
Graticule, a Real World Data CRO that conducts life science research and development projects with both USA and International data partners, is pleased to announce the onboarding of Patrick Hanson as the Chief Alliance Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831939371/en/
Patrick Wulf Hanson (Photo: Business Wire)
Daniel Poscover, Founder and CEO of Graticule, mentioned, “We are thrilled to welcome Patrick to our leadership team. With his vast experience in stakeholder management, engagement, and close interactions with Key Opinion Leaders (KOLs) and regulatory authorities, I am confident that we can broaden our EU operations to a much larger network.”
Patrick has over 30 years of experience in the pharmaceutical industry, consultancy, and academia. He previously served as Vice President for Real-World Data Alliances Europe at Lumanity, Head of Real World Data Strategy Europe and Canada at Parexel, Director of Real-World Analytics & Solutions Nordics (and Head of Denmark) at IQVIA, Nordic medical director at McCann Health Nordic, Scientific Director at Cohn & Wolfe and Molecule Consultancy, and Director of Global Product Safety, Regulatory Affairs Officer, and Corporate Branding at Novo Nordisk. Before his industry work, Patrick held research and teaching positions in Sweden, Denmark, and the USA. He has also authored textbooks and peer-reviewed articles.
Patrick's vast network and diverse European experience will help introduce innovative business strategies and foster collaborations for Graticule's European operations. Patrick believes that his ability to create sustainable relationships and alliances, stakeholder engagement, communicate advanced medical content to any audience, and create value for customers and patients will help Graticule in becoming a leading player in the European market.
To learn more, visit Graticule.
About Graticule
Graticule is a Real World Data CRO that conducts life science research and development projects with both USA and International data partners. The company focuses on establishing relationships, tools, and expertise to overcome traditional barriers that have limited the applications of medical data. Graticule solutions include comparative effectiveness studies, surveillance, patient identification, clinical trial recruitment, and an automated data transfer to Electronic Data Capture systems. The company differentiates itself by focusing on timely access to relevant patient data through close engagement with both Graticule Research Network and project-specific data partners. The result of the approach is a team that can rapidly leverage advanced data sets such as clinical notes, imaging, genetic testing, and structured clinical data and can scale research to large populations over time. Our solutions include Graticule Study Source, Graticule Patient Finder, and Graticule CLEHR.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831939371/en/
Contact information
Kyle F. Conley
Vice President of People Operations, Privacy Official
kconley@graticule.life
(617) 412-0999
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom